Evidence map›Paper›PMID 35940890›Full record

ArticleNeurology2022

Black Line Sign in Focal Cortical Dysplasia IIB: A 7T MRI and Electroclinicopathologic Study.

Yingying Tang, Ingmar Blümcke, Ting-Yu Su, Joon Yul Choi, Balu Krishnan, Hiroatsu Murakami, Andreas V Alexopoulos, Imad M Najm, Stephen E Jones, Zhong Irene Wang

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Neurology, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 4 papers.

0numbers the graph read from it
0cells of the map it votes in
4citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

4 citing papers in PubMed.

  1. Article
  2. Review
  3. Review
  4. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

10 authors.

Yingying TangFrom the Department of Neurology (Y.T.), West China Hospital of Sichuan University, Chengdu, Sichuan, China; Charles Shor Epilepsy Center (Y.T., I.B., T.-Y.S., J.Y.C., B.K., H.M., A.V.A., I.M.N., Z.I.W.), Cleveland Clinic; Department of Neuropathology (I.B.), University of Erlangen, Germany; Department of Biomedical Engineering (T.-Y.S.), Case Western Reserve University; and Imaging Institute (S.E.J.), Cleveland Clinic, OH.
Ingmar BlümckeFrom the Department of Neurology (Y.T.), West China Hospital of Sichuan University, Chengdu, Sichuan, China; Charles Shor Epilepsy Center (Y.T., I.B., T.-Y.S., J.Y.C., B.K., H.M., A.V.A., I.M.N., Z.I.W.), Cleveland Clinic; Department of Neuropathology (I.B.), University of Erlangen, Germany; Department of Biomedical Engineering (T.-Y.S.), Case Western Reserve University; and Imaging Institute (S.E.J.), Cleveland Clinic, OH.
Ting-Yu SuFrom the Department of Neurology (Y.T.), West China Hospital of Sichuan University, Chengdu, Sichuan, China; Charles Shor Epilepsy Center (Y.T., I.B., T.-Y.S., J.Y.C., B.K., H.M., A.V.A., I.M.N., Z.I.W.), Cleveland Clinic; Department of Neuropathology (I.B.), University of Erlangen, Germany; Department of Biomedical Engineering (T.-Y.S.), Case Western Reserve University; and Imaging Institute (S.E.J.), Cleveland Clinic, OH.
Joon Yul ChoiFrom the Department of Neurology (Y.T.), West China Hospital of Sichuan University, Chengdu, Sichuan, China; Charles Shor Epilepsy Center (Y.T., I.B., T.-Y.S., J.Y.C., B.K., H.M., A.V.A., I.M.N., Z.I.W.), Cleveland Clinic; Department of Neuropathology (I.B.), University of Erlangen, Germany; Department of Biomedical Engineering (T.-Y.S.), Case Western Reserve University; and Imaging Institute (S.E.J.), Cleveland Clinic, OH.
Balu KrishnanFrom the Department of Neurology (Y.T.), West China Hospital of Sichuan University, Chengdu, Sichuan, China; Charles Shor Epilepsy Center (Y.T., I.B., T.-Y.S., J.Y.C., B.K., H.M., A.V.A., I.M.N., Z.I.W.), Cleveland Clinic; Department of Neuropathology (I.B.), University of Erlangen, Germany; Department of Biomedical Engineering (T.-Y.S.), Case Western Reserve University; and Imaging Institute (S.E.J.), Cleveland Clinic, OH.
Hiroatsu MurakamiFrom the Department of Neurology (Y.T.), West China Hospital of Sichuan University, Chengdu, Sichuan, China; Charles Shor Epilepsy Center (Y.T., I.B., T.-Y.S., J.Y.C., B.K., H.M., A.V.A., I.M.N., Z.I.W.), Cleveland Clinic; Department of Neuropathology (I.B.), University of Erlangen, Germany; Department of Biomedical Engineering (T.-Y.S.), Case Western Reserve University; and Imaging Institute (S.E.J.), Cleveland Clinic, OH.
Andreas V AlexopoulosFrom the Department of Neurology (Y.T.), West China Hospital of Sichuan University, Chengdu, Sichuan, China; Charles Shor Epilepsy Center (Y.T., I.B., T.-Y.S., J.Y.C., B.K., H.M., A.V.A., I.M.N., Z.I.W.), Cleveland Clinic; Department of Neuropathology (I.B.), University of Erlangen, Germany; Department of Biomedical Engineering (T.-Y.S.), Case Western Reserve University; and Imaging Institute (S.E.J.), Cleveland Clinic, OH.ORCID https://orcid.org/0000-0003-0214-3286
Imad M NajmFrom the Department of Neurology (Y.T.), West China Hospital of Sichuan University, Chengdu, Sichuan, China; Charles Shor Epilepsy Center (Y.T., I.B., T.-Y.S., J.Y.C., B.K., H.M., A.V.A., I.M.N., Z.I.W.), Cleveland Clinic; Department of Neuropathology (I.B.), University of Erlangen, Germany; Department of Biomedical Engineering (T.-Y.S.), Case Western Reserve University; and Imaging Institute (S.E.J.), Cleveland Clinic, OH.
Stephen E JonesFrom the Department of Neurology (Y.T.), West China Hospital of Sichuan University, Chengdu, Sichuan, China; Charles Shor Epilepsy Center (Y.T., I.B., T.-Y.S., J.Y.C., B.K., H.M., A.V.A., I.M.N., Z.I.W.), Cleveland Clinic; Department of Neuropathology (I.B.), University of Erlangen, Germany; Department of Biomedical Engineering (T.-Y.S.), Case Western Reserve University; and Imaging Institute (S.E.J.), Cleveland Clinic, OH.
Zhong Irene WangFrom the Department of Neurology (Y.T.), West China Hospital of Sichuan University, Chengdu, Sichuan, China; Charles Shor Epilepsy Center (Y.T., I.B., T.-Y.S., J.Y.C., B.K., H.M., A.V.A., I.M.N., Z.I.W.), Cleveland Clinic; Department of Neuropathology (I.B.), University of Erlangen, Germany; Department of Biomedical Engineering (T.-Y.S.), Case Western Reserve University; and Imaging Institute (S.E.J.), Cleveland Clinic, OH. wangi2@ccf.org.

Funding

MR Fingerprinting for EpilepsyR01NS109439 · NINDS · CLEVELAND CLINIC LERNER COM-CWRU · PI Dan Ma, Zhong Irene Wang · 2019 to 2026
$4.2M
NINDS NIH HHS R01 NS109439
6 · The paper itself

Abstract

BACKGROUND AND

objectivesWe aim to provide detailed imaging-electroclinicopathologic characterization of the black line sign, a novel MRI marker for focal cortical dysplasia (FCD) IIB.

methods7T T2*-weighted gradient-echo (T2*w-GRE) images were retrospectively reviewed in a consecutive cohort of patients with medically intractable epilepsy with pathology-proven FCD II, for the occurrence of the black line sign. We examined the overlap between the black line region and the seizure-onset zone (SOZ) defined by intracranial EEG (ICEEG) and additionally assessed whether complete inclusion of the black line region in the surgical resection was associated with postoperative seizure freedom. The histopathologic specimen was aligned with the MRI to investigate the pathologic underpinning of the black line sign. Region-of-interest-based quantitative MRI (qMRI) analysis on the 7T T1 map was performed in the black line region, entire lesional gray matter (GM), and contralateral/ipsilateral normal gray and white matter (WM).

resultsWe included 20 patients with FCD II (14 IIB and 6 IIA). The black line sign was identified in 12/14 (85.7%) of FCD IIB and 0/6 of FCD IIA on 7T T2*w-GRE. The black line region was highly concordant with the ICEEG-defined SOZ (5/7 complete and 2/7 partial overlap). Seizure freedom was seen in 8/8 patients whose black line region was completely included in the surgical resection; in the 2 patients whose resection did not completely include the black line region, both had recurring seizures. Inclusion of the black line region in the surgical resection was significantly associated with seizure freedom ( DISCUSSION: The black line sign may serve as a noninvasive marker for FCD IIB. Both MRI-pathology and qMRI analyses suggest that the black line region was an abnormal GM component within the FCD. Being highly concordant with ICEEG-defined SOZ and significantly associated with seizure freedom when included in resection, the black line sign may contribute to the planning of ICEEG/surgery of patients with medically intractable epilepsy with FCD IIB. CLASSIFICATION OF EVIDENCE: This study provides Class II evidence that in individuals with intractable focal epilepsy undergoing resection who have a 7T MRI with adequate image quality, the presence of the black line sign may suggest FCD IIB, be concordant with SOZ from ICEEG, and be associated with more seizure freedom if fully included in resection.

Indexed as

Drug Resistant EpilepsyEpilepsies, PartialMalformations of Cortical DevelopmentHumansMagnetic Resonance ImagingRetrospective StudiesSeizures

Identifiers

PMID35940890
PMCPMC9442623

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.